Showing results (331-340 of 432) with videos related to

Sort By:
Pageof 44
Blood Advances|October 8, 2025
Transplantation in lower risk MDS patients: a prospective phase 2 trial based on donor availabilityMarie Sebert, Sylvain Thepot, Thomas Cluzeau, et al.
Blood Advances|April 12, 2022
Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trialMarina Y Konopleva, Christoph Röllig, Jamie Cavenagh, et al.
Autoimmunity Reviews|July 15, 2017
Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patientsArsene Mekinian, Guillaume Dervin, Nathanael Lapidus, et al.
Leukemia|March 10, 2026
Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?Dorothée Selimoglu-Buet, Sylvie Chevret, Valeria Santini, et al.
Blood|October 24, 2002
M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Français d'Hématologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH)Christophe Roumier, Virginie Eclache, Michelle Imbert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2021
Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i>-Mutant Myelodysplastic SyndromesDavid A Sallman, Amy E DeZern, Guillermo Garcia-Manero, et al.
Blood Advances|January 6, 2023
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry studyIgor Stojkov, Annette Conrads-Frank, Ursula Rochau, et al.
The Lancet. Haematology|July 21, 2024
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trialMaría Díez-Campelo, Félix López-Cadenas, Blanca Xicoy, et al.
Blood Advances|June 5, 2023
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized studyPierre Fenaux, Marco Gobbi, Patricia L Kropf, et al.
The Lancet. Haematology|July 14, 2023
Sickle cell disease landscape and challenges in the EU: the ERN-EuroBloodNet perspectiveMaría Del Mar Mañú Pereira, Raffaella Colombatti, Federico Alvarez, et al.
Pageof 44